END - VT Cohort Study

Launched by NOVA SCOTIA HEALTH AUTHORITY · Apr 26, 2023

Keywords

ClinConnect Summary

The END - VT Cohort Study is a clinical trial that aims to find the best treatment strategies for patients who have ventricular tachycardia (VT), a serious heart rhythm problem that can lead to sudden cardiac death. The study will focus on patients who have cardiomyopathy, a condition where the heart muscle is damaged or weakened. While implantable cardiac defibrillators (ICDs) are effective at preventing sudden cardiac death, they cannot completely eliminate the risk of VT returning. This trial will explore how to improve patient outcomes and reduce the chances of further heart issues.

To participate in this study, you must be over 18 years old and have a documented case of sustained VT, which means your heart was beating too quickly for more than 30 seconds. You should also have a diagnosis of cardiomyopathy and plan to have an ICD implanted during your hospital stay. If eligible, you will be part of a group that will be followed over time to see how well different treatments work and how safe they are. This research is being conducted in multiple centers across Canada, and by participating, you will help improve the understanding of VT and its management for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Documented sustained ventricular arrhythmia (\>30 seconds as documented by an ECG, cardiac monitor, AED, and/or intracardiac pacemaker/ICD electrograms (EGMs);
• • 2. First (new) diagnosis of VT;
• • 3. Presence of or plan for ICD implant during index hospitalization;
• • 4. Diagnosis of cardiomyopathy (ie. ICM, hypertrophic, dilated, restrictive, arrhythmogenic cardiomyopathy, or other scar),
• • 5. ICD clinic follow-up planned, and
• • 6. Age \>18 years old
• Exclusion Criteria:
• • 1) Patients with VT due to a reversible cause